ASCO 2024

Questions discussed in this category

What are your top takeaways in Gyn Cancers from ASCO 2024?

How do you decide between treating with neoadjuvant nivolumab/ipilimumab versus neoadjuvant pembrolizumab for patients with resectable, clinical node + Stage III melanoma given the NADINA trial results?

1 Answer available

Given the results of ESOPEC from ASCO 2024, for which patients with resectable esophageal adenocarcinoma would you favor neoadjuvant chemoradiation?

ESOPEC compared perioperative FLOT vs neoadjuvant chemoradiation per the CROSS trial, and showed superior OS with perioperative FLOT. What concerns do...

3 Answers available

Based on the DREAMM-7 and DREAMM-8 data, if approved again in the US, how would you incorporate belantamab mafadotin in your practice?

2 Answers available

Based on the IMROZ and BENEFIT data, would you recommend quadruplet therapy for non transplant eligible newly diagnosed multiple myeloma?

1 Answer available

Would you offer consolidative radiotherapy for oligometastatic NSCLC?

Given that LU002 has failed to meet its progression free survival benefit in results presented at ASCO, will you offer consolidative radiotherapy for ...

1 Answer available

What are your top takeaways from ASCO GI 2024?

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice...

1 Answer available

What are your top takeaways from ASCO GU 2024?

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical prac...

4 Answers available